Therapeutic targeting of the host-microbiota-immune axis: implications for precision health

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 29, 2025

The human body functions as a complex ecosystem, hosting trillions of microbes that collectively form the microbiome, pivotal in immune system regulation. host-microbe immunological axis maintains homeostasis and influences key physiological processes, including metabolism, epithelial integrity, neural function. Recent advancements microbiome-based therapeutics, probiotics, prebiotics fecal microbiota transplantation, offer promising strategies for modulation. Microbial therapies leveraging microbial metabolites engineered bacterial consortia are emerging novel therapeutic strategies. However, significant challenges remain, individual microbiome variability, complexity interactions, need precise mechanistic insights. This review comprehensively examines host elucidating its mechanisms, potential, future directions immunomodulation health. It will also critically evaluate challenges, limitations, precision medicine.

Language: Английский

Disputes and Challenges of Immune Checkpoint Inhibitors in Gastrointestinal Cancers

Frontiers research topics, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

it is a pioneering approach to the world of academia, radically improving way scholarly research managed.The grand vision Frontiers where all people have an equal opportunity seek, share and generate knowledge.Frontiers provides immediate permanent online open access its publications, but this alone not enough realize our goals. journal seriesThe series multi-tier interdisciplinary set openaccess, journals, promising paradigm shift from current review, selection dissemination processes in academic publishing.All journals are driven by researchers for researchers; therefore, they constitute service community.At same time, operates on revolutionary invention, tiered publishing system, initially addressing specific communities scholars, gradually climbing up broader public understanding, thus serving interests lay society, too. Dedication qualityEach article landmark highest quality, thanks genuinely collaborative interactions between authors review editors, who include some world's best academicians.Research must be certified peers before entering stream knowledge that may eventually reach -and shape society; only applies most rigorous unbiased reviews.Frontiers revolutionizes freely delivering outstanding research, evaluated with no bias both social point view.By applying advanced information technologies, catapulting into new generation.

Language: Английский

The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 24, 2024

Background The occurrence of immune-related adverse events (irAEs) seemed to be associated with better outcomes in advanced gastric cancer (AGC) patients. However, research focusing on the impact single-organ irAE (uni-irAE) or multi-organ irAEs (multi-irAEs) AGC outcome is relatively limited. In this study, we investigated individually different survival as well co-occurrence patterns multi-irAEs. Methods uni-irAE, multi-irAEs, and non-irAE were identified based National Comprehensive Cancer Network (NCCN) guidelines. ICI efficacy for disease control rate (DCR) objective response (ORR) was assessed Response Evaluation Criteria Solid Tumors (RECIST) Version 1.1. association progression-free (PFS) overall (OS) analyzed using Kaplan–Meier method Cox regression model. We also performed pairwise correlation analysis identify irAEs. Results A total 288 patients including 175 non-irAE, 73 40 multi-irAE evaluated their outcome. displayed higher DCR (78.8% vs. 67.4%, p =0.037) when compared those patients, both uni-irAE (82.2% =0.019) (72.5% =0.534) showed than that multivariate analyses revealed multi-irAEs an independent risk factor PFS (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41~0.96, =0.031) OS (HR 0.47, CI 0.29~0.76, =0.002), whereas not obtained. thyroid, adrenal gland, heart, skin, lung exhibited a high organ-specific experiencing skin had favorable without these Conclusion Multi-irAEs some can used predictive indicators treatment are often accompanied by occurrence.

Language: Английский